[go: up one dir, main page]

CL2016002589A1 - Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348). - Google Patents

Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).

Info

Publication number
CL2016002589A1
CL2016002589A1 CL2016002589A CL2016002589A CL2016002589A1 CL 2016002589 A1 CL2016002589 A1 CL 2016002589A1 CL 2016002589 A CL2016002589 A CL 2016002589A CL 2016002589 A CL2016002589 A CL 2016002589A CL 2016002589 A1 CL2016002589 A1 CL 2016002589A1
Authority
CL
Chile
Prior art keywords
disease
eliglustat
genz
compound
treatment
Prior art date
Application number
CL2016002589A
Other languages
English (en)
Inventor
John Marshall
Seng Cheng
Craig Siegel
Chris Willis
Diane P Copeland
Abizer Harianawala
Jeffrey Skell
Jianmei Kochling
Gerard Palace
Judith Peter-Schmitt
Renu Bhardwaj
Harlan Liu
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002589(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CL2016002589A1 publication Critical patent/CL2016002589A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Molecular Biology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

USO DEL COMPUESTO GENZ-112638 (ELIGLUSTAT), INHIBIDOR DE GLUCOSILCERAMIDA SINTASA, EN EL TRATAMIENTO DE LA ENFERMEDAD DE GAUCHER Y ENFERMEDAD DE FABRY (DIVISIONAL DE SOLICITUD 201201348).
CL2016002589A 2009-11-27 2016-10-12 Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348). CL2016002589A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26474809P 2009-11-27 2009-11-27

Publications (1)

Publication Number Publication Date
CL2016002589A1 true CL2016002589A1 (es) 2017-05-19

Family

ID=43431870

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2012001348A CL2012001348A1 (es) 2009-11-27 2012-05-24 Sal cristalina de hemitartrato del compuesto genz-112638, inhibidor de glucosilceramida sintetasa; composición farmacéutica que la comprende;y su uso en el tratamiento de la enfermedad de gaucher y enfermedad de fabry.
CL2016002589A CL2016002589A1 (es) 2009-11-27 2016-10-12 Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2012001348A CL2012001348A1 (es) 2009-11-27 2012-05-24 Sal cristalina de hemitartrato del compuesto genz-112638, inhibidor de glucosilceramida sintetasa; composición farmacéutica que la comprende;y su uso en el tratamiento de la enfermedad de gaucher y enfermedad de fabry.

Country Status (40)

Country Link
US (6) US11458119B2 (es)
EP (5) EP3599237B1 (es)
JP (6) JP2013512252A (es)
KR (6) KR20250005503A (es)
CN (5) CN105777707B (es)
AR (3) AR079152A1 (es)
AU (3) AU2010324810B2 (es)
BR (1) BR112012012947B8 (es)
CA (3) CA3075788C (es)
CL (2) CL2012001348A1 (es)
CR (1) CR20120277A (es)
CY (3) CY1115880T1 (es)
DK (3) DK2796457T3 (es)
DO (2) DOP2012000141A (es)
EA (3) EA029990B1 (es)
EC (2) ECSP12011926A (es)
ES (4) ES2493940T5 (es)
GT (1) GT201200161A (es)
HR (3) HRP20140780T4 (es)
HU (2) HUE029371T2 (es)
IL (4) IL310635A (es)
LT (2) LT2796457T (es)
MA (1) MA33838B1 (es)
ME (1) ME02477B (es)
MX (2) MX381242B (es)
MY (2) MY160542A (es)
NI (1) NI201200096A (es)
NZ (3) NZ600155A (es)
PE (2) PE20121337A1 (es)
PH (2) PH12015502514B1 (es)
PL (4) PL2796457T3 (es)
PT (4) PT2796457T (es)
RS (3) RS59543B1 (es)
SG (2) SG10201407881WA (es)
SI (3) SI2796457T1 (es)
SM (1) SMT201600273B (es)
TN (1) TN2012000237A1 (es)
TW (3) TWI586663B (es)
UA (1) UA113491C2 (es)
WO (1) WO2011066352A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
SG10201407881WA (en) 2009-11-27 2015-01-29 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
ES2664844T3 (es) * 2011-06-20 2018-04-23 Mount Sinai School Of Medicine Tratamiento dirigido contra TNF para las mucopolisacaridosis y otros trastornos lisosómicos
US10350277B2 (en) 2011-09-07 2019-07-16 Icahn School Of Medicine At Mount Sinai Ceramidase and cell differentiation
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
EP3679923B1 (en) 2012-06-01 2021-08-04 Icahn School of Medicine at Mount Sinai Ceramide levels in the treatment and prevention of infections
HUE046113T2 (hu) 2013-03-14 2020-02-28 Icahn School Med Mount Sinai Terápiás sav ceramidáz készítmények és azok elõállítási és felhasználási eljárásai
EP3912977A1 (en) * 2013-09-20 2021-11-24 BioMarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
WO2016001885A2 (en) * 2014-07-03 2016-01-07 Dr. Reddy’S Laboratories Limited Amorphous form of eliglustat hemitartarate
EP3283483B1 (en) 2015-04-14 2018-12-19 Sandoz AG Crystalline eliglustat hydrochloride
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
AU2016357720A1 (en) 2015-11-18 2018-07-05 Genzyme Corporation Biomarker of polycystic kidney disease and uses thereof
EA201891438A1 (ru) 2016-02-25 2019-01-31 Асенейрон С. А. Кислотно-аддитивные соли производных пиперазина
CN107445938B (zh) * 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
WO2018225085A1 (en) 2017-06-05 2018-12-13 Cipla Limited Stable solid dispersions of eliglustat hemitartrate
WO2018232235A1 (en) * 2017-06-16 2018-12-20 Beta Pharma, Inc. Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
US20200197366A1 (en) * 2017-08-08 2020-06-25 Kashiv Biosciences, Llc Pharmaceutical composition comprising eliglustat
US12472144B2 (en) * 2017-08-08 2025-11-18 Amneal Pharmaceuticals Llc Pharmaceutical composition comprising eliglustat
JP2021506789A (ja) * 2017-12-15 2021-02-22 ジェンザイム・コーポレーション ゴーシェ病を処置する方法
WO2019123476A1 (en) * 2017-12-20 2019-06-27 Sarudbhava Formulations Private Limited Stable amorphous eliglustat premix and process for the preparation thereof
WO2019211778A2 (en) * 2018-05-02 2019-11-07 Kashiv Biosciences, Llc Pro-drugs of eliglustat
AU2019276882A1 (en) * 2018-05-27 2021-01-14 Bioasis Technolgies Inc. Treatment of gaucher disease
CN110878079A (zh) * 2018-12-31 2020-03-13 北京启慧生物医药有限公司 一种高纯度依利格鲁司他的制备方法
CN118076356A (zh) * 2021-07-05 2024-05-24 菲尔若国际公司 包含糖苷酶抑制剂的药剂
CN116120274A (zh) * 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
US5302609A (en) 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US5707649A (en) 1993-08-13 1998-01-13 Seikagaku Corporation Agent for treating neuronal diseases
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
DK0742789T3 (da) 1994-02-02 2000-11-13 Liposome Co Inc Farmaceutisk aktive forbindelser og liposomer og fremgangsmåder til anvendelse af disse
EP0765865B1 (en) 1994-06-10 2001-12-12 Seikagaku Corporation 2-acylaminopropanol compound and medicinal composition
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US5916911A (en) 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP3993908B2 (ja) 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
AU756008B2 (en) 1998-07-27 2003-01-02 Johns Hopkins University, The Methods for treating conditions modulated by lactosylceramide
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
EP1384719A1 (en) 1999-07-09 2004-01-28 The Regents of The University of Michigan Inhibitors of the glucosyl ceramide synthase enzyme useful for the treatment of cancers, sphingolipidosis and microbial infections
BR0012318A (pt) * 1999-07-09 2002-05-28 Univ Michigan Compostos semelhantes a amino ceramida e métodos terapêuticos de uso
MXPA02006660A (es) * 2000-01-07 2002-12-13 Transform Pharmaceuticals Inc Formacion, identificacion y analisis de diversas formas solidas de alto rendimiento.
US6977723B2 (en) 2000-01-07 2005-12-20 Transform Pharmaceuticals, Inc. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
ES2277301T3 (es) 2000-04-24 2007-07-01 Teva Pharmaceutical Industries Ltd. Solvato de hemitartrato de zolpidem.
US6436987B1 (en) 2000-06-08 2002-08-20 Pfizer Inc. Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
EP1358172B1 (en) 2001-01-10 2009-11-18 The Regents of The University of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
HUP0401300A3 (en) * 2001-01-18 2005-06-28 Merck Patent Gmbh Bifunctional fusion proteins with glucocerebrosidase activity
US6855830B2 (en) * 2001-07-16 2005-02-15 Genzyme Corporation Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
EP1281755A3 (en) 2001-07-31 2003-06-18 Pfizer Products Inc. Variants of the human cyp2d6 gene
PT2206702E (pt) 2001-08-08 2012-02-03 Tobira Therapeutics Inc Composto bicíclico, sua produção e utilização
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
JP2005535665A (ja) 2002-07-09 2005-11-24 ザ スクリプス リサーチ インスティテュート 虚血および再灌流損傷を防止する方法
US20050032070A1 (en) 2003-08-05 2005-02-10 Sebastian Raimundo Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications
DE602005027308D1 (de) * 2004-01-27 2011-05-19 Synthon Bv Stabile salze von olanzapin
JP5302537B2 (ja) 2004-09-17 2013-10-02 ユニバーシティ オブ マサチューセッツ リソソーム酵素欠損症のための組成物およびそれらの使用
WO2006039663A2 (en) 2004-09-30 2006-04-13 Vanda Pharmaceuticals, Inc Methods for the administration of iloperidone
CA2584246C (en) 2004-10-13 2011-08-09 Pharmacia & Upjohn Company Llc Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide
BRPI0517701A8 (pt) * 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
US20070088082A1 (en) * 2005-09-28 2007-04-19 Judith Aronhime Polymorphic forms of ladostigil tartrate
WO2007040995A1 (en) * 2005-10-03 2007-04-12 Mallinckrodt Inc. Process for preparing zolpidem hemitartrate and tartrate polymorphs
MX2007016179A (es) 2006-04-17 2008-03-11 Teva Pharma Formas cristalinas de o-desmetilvenlafaxina.
WO2007134086A2 (en) * 2006-05-09 2007-11-22 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
KR101271225B1 (ko) 2006-10-31 2013-06-03 삼성디스플레이 주식회사 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법
TWI314226B (en) 2006-12-07 2009-09-01 Ind Tech Res Inst Piezoelectricity-driving optical lens module
EP1961765A1 (en) 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
BRPI0806543A2 (pt) * 2007-01-12 2014-04-22 Wyeth Corp Composições de comprimido em comprimido
JP2010523578A (ja) * 2007-03-30 2010-07-15 アミカス セラピューティックス インコーポレイテッド 薬理シャペロンを用いるファブリー病の治療方法
AU2008245578A1 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2594564B1 (en) * 2007-05-31 2016-09-28 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
DE102007029581B4 (de) 2007-06-26 2020-04-09 GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) Kraftfahrzeugdach und Kraftfahrzeugkarosserie
US20090307181A1 (en) 2008-03-19 2009-12-10 Brandon Colby Genetic analysis
WO2009117150A2 (en) 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
KR102668834B1 (ko) 2009-11-27 2024-05-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
SG10201407881WA (en) 2009-11-27 2015-01-29 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
ES2775902T3 (es) 2009-11-27 2020-07-28 Adverio Pharma Gmbh Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1H-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo
WO2012175522A1 (en) 2011-06-21 2012-12-27 Novartis Ag Polymorphs of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
JP6728842B2 (ja) 2016-03-24 2020-07-22 オムロン株式会社 光学計測装置
CN107445938B (zh) 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof

Also Published As

Publication number Publication date
US20130137743A1 (en) 2013-05-30
DOP2016000250A (es) 2017-02-15
CY1122698T1 (el) 2021-03-12
CA2781676C (en) 2020-05-05
ES2493940T5 (es) 2021-11-23
JP2020189873A (ja) 2020-11-26
NZ600155A (en) 2014-10-31
UA113491C2 (xx) 2017-02-10
KR20200013105A (ko) 2020-02-05
CN105753846B (zh) 2019-11-15
TW201130822A (en) 2011-09-16
PH12015502514B1 (en) 2022-07-29
US20160166542A1 (en) 2016-06-16
DOP2012000141A (es) 2012-09-30
JP2023116764A (ja) 2023-08-22
EP2504332B1 (en) 2014-06-04
CA3075788A1 (en) 2011-06-03
CA3140959A1 (en) 2011-06-03
SI2504332T1 (sl) 2014-09-30
TWI606827B (zh) 2017-12-01
JP7150528B2 (ja) 2022-10-11
SI3133070T1 (sl) 2019-11-29
SI2504332T2 (sl) 2021-08-31
PL3599237T3 (pl) 2021-09-27
AU2017265180B2 (en) 2019-08-01
PL2796457T3 (pl) 2017-04-28
KR20220162824A (ko) 2022-12-08
AU2016202591A1 (en) 2016-05-19
PT3133070T (pt) 2019-11-11
MX2012006083A (es) 2012-06-19
ES2875382T3 (es) 2021-11-10
US20210393590A1 (en) 2021-12-23
PH12015502514A1 (en) 2016-08-15
MA33838B1 (fr) 2012-12-03
KR102073207B1 (ko) 2020-02-05
MX358345B (es) 2018-08-14
MY192644A (en) 2022-08-29
EP3599237A1 (en) 2020-01-29
IL260299A (en) 2018-08-30
CA3075788C (en) 2021-12-21
CY1117996T1 (el) 2017-05-17
HRP20140780T4 (hr) 2021-08-06
GT201200161A (es) 2014-01-27
PH12012501048A1 (en) 2013-02-04
EA201890254A2 (ru) 2018-10-31
TN2012000237A1 (en) 2013-12-12
PT2504332E (pt) 2014-09-02
ES2586947T3 (es) 2016-10-19
EP2796457A1 (en) 2014-10-29
EP3133070A1 (en) 2017-02-22
SMT201600273B (it) 2016-08-31
US11458119B2 (en) 2022-10-04
IL283935A (en) 2021-07-29
KR20150125734A (ko) 2015-11-09
EP3599237B1 (en) 2021-03-24
AU2016202591B2 (en) 2017-11-30
EP2504332A1 (en) 2012-10-03
DK2504332T3 (da) 2014-08-25
ECSP18063798A (es) 2020-02-28
NZ625712A (en) 2016-02-26
PE20121337A1 (es) 2012-10-12
NI201200096A (es) 2012-10-30
EP2504332B2 (en) 2021-03-17
CN105777707B (zh) 2020-10-13
PT2796457T (pt) 2016-07-14
ME02477B (me) 2017-02-20
AU2010324810B2 (en) 2016-05-12
CN105753846A (zh) 2016-07-13
BR112012012947A2 (pt) 2017-03-01
PL2504332T5 (pl) 2021-08-23
CR20120277A (es) 2012-09-05
JP2016138124A (ja) 2016-08-04
HRP20161038T1 (hr) 2016-10-21
DK3133070T3 (da) 2019-11-11
HRP20191647T1 (hr) 2019-12-13
WO2011066352A1 (en) 2011-06-03
LT3133070T (lt) 2019-11-11
JP2019001809A (ja) 2019-01-10
CY1115880T1 (el) 2017-01-25
JP2013512252A (ja) 2013-04-11
WO2011066352A8 (en) 2011-08-11
CN112521366A (zh) 2021-03-19
SI2796457T1 (sl) 2016-10-28
TWI656873B (zh) 2019-04-21
LT2796457T (lt) 2016-09-12
EP3896069A1 (en) 2021-10-20
EP3133070B1 (en) 2019-08-14
TWI586663B (zh) 2017-06-11
RS54978B1 (sr) 2016-11-30
CN102712629A (zh) 2012-10-03
MY160542A (en) 2017-03-15
KR20180049255A (ko) 2018-05-10
ES2754398T3 (es) 2020-04-17
HUE029371T2 (en) 2017-02-28
US10888547B2 (en) 2021-01-12
RS53503B2 (sr) 2021-07-30
JP6370264B2 (ja) 2018-08-08
TW201737910A (zh) 2017-11-01
EA029990B1 (ru) 2018-06-29
DK2504332T4 (da) 2021-06-07
CN112521367B (zh) 2024-01-02
EA201890254A3 (ru) 2019-02-28
HK1203485A1 (en) 2015-10-30
AR121611A2 (es) 2022-06-22
DK2796457T3 (en) 2016-08-29
ES2493940T3 (es) 2014-09-12
BR112012012947B8 (pt) 2021-05-25
PE20171255A1 (es) 2017-08-28
CL2012001348A1 (es) 2012-08-24
US20210369672A1 (en) 2021-12-02
RS53503B1 (en) 2015-02-27
PT3599237T (pt) 2021-04-28
SG10201800136QA (en) 2018-02-27
US20160120842A1 (en) 2016-05-05
KR20250005503A (ko) 2025-01-09
ECSP12011926A (es) 2012-07-31
PL3133070T3 (pl) 2020-01-31
SG10201407881WA (en) 2015-01-29
AR079152A1 (es) 2011-12-28
CN112521367A (zh) 2021-03-19
CN102712629B (zh) 2016-10-12
EA023923B1 (ru) 2016-07-29
BR112012012947B1 (pt) 2021-04-06
CA2781676A1 (en) 2011-06-03
CN105777707A (zh) 2016-07-20
KR20120115972A (ko) 2012-10-19
HK1172031A1 (en) 2013-04-12
AU2010324810A1 (en) 2012-06-07
PL2504332T3 (pl) 2014-10-31
JP2015212291A (ja) 2015-11-26
TW201639562A (zh) 2016-11-16
EA201592195A1 (ru) 2016-04-29
EP2796457B1 (en) 2016-05-18
US20230172903A1 (en) 2023-06-08
IL310635A (en) 2024-04-01
AU2017265180A1 (en) 2017-12-14
NZ715108A (en) 2017-06-30
AR121612A2 (es) 2022-06-22
US12465586B2 (en) 2025-11-11
EA201270646A1 (ru) 2013-01-30
HUE045784T2 (hu) 2020-01-28
HRP20140780T1 (en) 2014-11-07
JP6452635B2 (ja) 2019-01-16
IL219892A0 (en) 2012-07-31
RS59543B1 (sr) 2019-12-31
MX381242B (es) 2025-03-12

Similar Documents

Publication Publication Date Title
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
CY1120961T1 (el) Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
CR20110658A (es) Antagonistas de la trayectoria hedgehog de ftalazina desustituida
ECSP11010975A (es) Método de uso de una cepa de bacillus subtilis para mejorar la salud de animales
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
CL2011002787A1 (es) Compuestos derivados de 1-cianoetilheterociclilcarboxamida sustituidos, inhibidores de dipeptidilpeptidasa i (dppi) o catepsina c; composicion farmaceutica; combinacion faramceutica; y su uso en el tratamiento del asma, la enfermedad obstructiva cronica o la rinitis alergica.
NO20083630L (no) Nye pyridinderivater
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
MA32349B1 (fr) Antagonistes de la voie hedgehog a base de phtalazines disubstituees
ECSP11011021A (es) Antagonistas de la via hedgehog de ftalazina disustituida
NI201000015A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
NO20082298L (no) Kaliumkanalinhibitorer
TW200942524A (en) Novel aminomethyl benzene derivatives
TW200942530A (en) Pyridine compounds
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.
MX2010010876A (es) Piperidinas sustituidas como compuestos terapeuticos.
CL2009000257A1 (es) Uso de imidazolinas 1,3 sustituidas y de sus sales fisiologicamente compatibles para el tratamiento del sindrome metabolico.
AR072426A1 (es) Uso de nifurtimox para el tratamiento de enfermedades causadas por tricomonadida
ECSP10010552A (es) Asociacion de LA dronedarona con al menos un diuretico, su aplicacion en terapeutica
AR082594A1 (es) Docosahexanoato de pantenilo y su uso para el tratamiento y prevencion de enfermedades cardiovasculares
AR067351A1 (es) Combinacion de picotamida con nafronil
CL2007001794A1 (es) Compuestos derivados de 2-imidazolidinona, inhibidores del canal de potasio kv1.5; composicion farmaceutica que los comprende; y su uso para tratar o prevenir arritmias cardiacas. tromboembolia,apoplejia,insuficiencia cardiaca.